Glassia Approval History
FDA Approved: Yes (First approved July 1, 2010)
Trade names: Glassia
Generic name: alpha1-proteinase inhibitor (human)
Routes of administration: Injection
Previous Name: AAT-IV
Company: Kamada Ltd.
Target disease: Alpha-1 Proteinase Inhibitor Deficiency
Pregnancy Category: US: B (No risks have been found in humans.)
ATC code: B02AB02
Glassia is an alpha1-proteinase inhibitor that is indicated for chronic augmentation and maintenance therapy in adults with emphysema due to congenital deficiency of alpha1-proteinase inhibitor (Alpha1-PI), also known as alpha1antitrypsin deficiency.
Development History and FDA Approval Process for Glassia
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.